Organovo Announces Pre-Release Availability of 3D Liver Contract Services

  Organovo Announces Pre-Release Availability of 3D Liver Contract Services

PR Newswire

SAN DIEGO, April 28, 2014

SAN DIEGO, April 28, 2014 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT:
ONVO) ("Organovo"), a three-dimensional biology company focused on delivering
breakthrough 3D bioprinting technology, today announced that it has initiated
contracting for toxicity testing using its 3D Human Liver Tissue for selected
clients prior to full release.

Organovo's Chairman and Chief Executive Officer, Keith Murphy, commented
"Organovo has received interest in advance of our planned launch from top 15
pharma company customers, small to midsize pharma companies, biotechnology
companies, and private venture capital backed pharmaceutical development
firms. The compelling data already generated on the performance of the 3D
Human Liver Tissue has driven this interest, we believe, and I'm pleased that
our team was able in a short time to accomplish all of the hard work that
allowed us to begin signing contracts. We'll be able to deliver results for
proprietary compounds and other needs, while completing the work for fuller
product and service launch on our original timeline."

Organovo is making 3D Human Liver Tissue technology available to clients who
have specific testing needs in their preclinical drug discovery programs. The
company has begun signing research service contracts and is in discussions
with additional customers for near-term needs, in a limited initial release of
this service. Customers with needs in a research setting that align with the
preliminary offering will be able to engage in the coming months, with fuller
testing services including metabolic function to be offered over time. All
testing will be performed at Organovo's facility by the Company's laboratory
services tissue experts.

The Company believes that its 3D Human Liver tissue model represents a new and
novel approach to the drug discovery and development process, providing
significant added value to preclinical assessment studies. The long lasting
viability and function of the tissue allows for extended study durations in
vitro, enabling the assessment of the effects of low dose or repeated dosing
regimens across a spectrum of biochemical, molecular, and histologic end
points.

For more information or to discuss specific study requirements, clients can
contact us at sales@organovo.com.

About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for
medical research and therapeutic applications. The Company is collaborating
with pharmaceutical and academic partners to develop human biological disease
models in three dimensions. These 3D human tissues have the potential to
accelerate the drug discovery process, enabling treatments to be developed
faster and at lower cost. In addition to numerous scientific publications, the
Company's technology has been featured in The Wall Street Journal, Time
Magazine, The Economist, and numerous others. Organovo is changing the shape
of medical research and practice. Learn more at www.organovo.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is defined in the
Private Securities Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on current expectations, but are subject
to a number of risks and uncertainties. The factors that could cause actual
future results to differ materially from current expectations include, but are
not limited to, risks and uncertainties relating to the Company's ability to
develop, market and sell products based on its technology; the expected
benefits and efficacy of the Company's products and technology; the market
acceptance of the Company's products; and the Company's business, research,
product development, regulatory approval, marketing and distribution plans and
strategies. These and other factors are identified and described in more
detail in our filings with the SEC, including our prospectus supplement filed
with the SEC on November 27, 2013 and our transition report on Form 10-KT
filed with the SEC on May 24, 2013 as well as our other filings with the
Securities and Exchange Commission. You should not place undue reliance on
these forward-looking statements, which speak only as of the date that they
were made. These cautionary statements should be considered with any written
or oral forward-looking statements that we may issue in the future. Except as
required by applicable law, including the securities laws of the United
States, we do not intend to update any of the forward-looking statements to
conform these statements to reflect actual results, later events or
circumstances or to reflect the occurrence of unanticipated events.

SOURCE Organovo Holdings, Inc.

Website: http://www.organovo.com
Contact: Investor Contact, Barry Michaels, Chief Financial Officer,
858-224-1000, ext. 3, IR@organovo.com, or Gerry Amato, Booke & Company
Investor Relations, admin@bookeandco.com; Media Contact, Mike Renard, EVP,
Commercial Operations, 858-224-1006, mrenard@organovo.com
 
Press spacebar to pause and continue. Press esc to stop.